Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

Moleculin's MIRACLE Trial Nears Unblinding with Promising Blinded Efficacy

Moleculin Biotech announced that its pivotal Phase 2B/3 MIRACLE trial, evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (R/R AML), is nearing its first unblinding of data from 45 subjects. Preliminary blinded efficacy data show a composite complete remission rate (CRc) exceeding 40% and a complete remission (CR) rate of approximately 30%. These results significantly outperform historical CR rates of 17-18% observed with cytarabine alone in similar patient populations. The trial targets a high-unmet-need AML population, including those relapsed or refractory to prior venetoclax regimens, and continues to demonstrate an absence of cardiotoxicity. The unblinding is expected before June 30, 2026, positioning Annamycin as a potential significant advancement in AML treatment.

• Promising Preliminary Efficacy Data: The MIRACLE trial's preliminary blinded data for the first 45 subjects reveal a composite complete remission rate (CRc) exceeding 40% and a complete remission (CR) rate of approximately 30%. These figures represent a substantial improvement compared to historical CR rates of 17-18% seen with cytarabine monotherapy, the current standard of care for second-line AML. This early indication suggests Annamycin, in combination with cytarabine, could offer a significant therapeutic advantage for patients with relapsed or refractory AML.
• Strategic Trial Design and Patient Population: The Phase 2B/3 MIRACLE trial is a global, multi-center, randomized, double-blind, placebo-controlled, adaptive study. It evaluates two Annamycin dosing arms (190 mg/m² and 230 mg/m²) combined with cytarabine against a control arm of cytarabine plus placebo. The trial specifically targets a challenging patient population: those with relapsed or refractory AML after a single prior induction therapy (2nd line), including a significant proportion (over 30%) who were previously refractory to venetoclax regimens.
• Favorable Safety Profile and Regulatory Status: Annamycin is highlighted for its ability to avoid multidrug resistance mechanisms and its lack of cardiotoxicity, a common issue with other anthracyclines. This favorable safety profile is crucial for AML patients, many of whom are older (median age in mid-60s). Furthermore, Annamycin holds Fast Track Status and Orphan Drug Designation from the FDA for R/R AML, along with Orphan Drug Designation from the EMA, underscoring its potential to address a high unmet medical need.

Addressing the High Unmet Need in R/R AML

Acute myeloid leukemia continues to present significant therapeutic challenges, particularly in relapsed/refractory disease and elderly populations. Despite recent advances in targeted therapies and less intensive treatment regimens, substantial unmet medical needs persist across multiple patient subgroups. The evolving treatment landscape has shifted toward personalized approaches, though gaps remain in achieving durable remissions and addressing therapy resistance.

• Relapsed/refractory AML patients represent the highest unmet need, with no standardized effective regimen, low remission rates, short survival, and poor prognosis despite conventional cytotoxic chemotherapies and allogeneic transplantation

• Elderly patients (median age 70 years) face intrinsically resistant disease that tends to be resistant to conventional chemotherapy, with standard intensive therapy being difficult to tolerate in this population who are predominantly affected by AML

• TP53-mutated AML patients remain a particular unmet need, though immune checkpoint inhibitors combined with hypomethylating agents show enhanced activity in this population

• FLT3-mutated AML patients (occurring in about 30% of cases) are being targeted with approved therapies including midostaurin, gilteritinib, and quizartinib, with FLT3-ITD associated with particularly poor prognosis

• IDH1/2-mutated AML patients are being addressed with approved inhibitors enasidenib and ivosidenib, with triplet regimens showing 92% composite complete remission rates in newly diagnosed intensive chemotherapy-ineligible patients

• Secondary AML patients experience inferior outcomes, with CPX-351 becoming a standard treatment for elderly patients with secondary AML

• Wild-type FLT3 relapsed/refractory patients face significant therapeutic challenges due to persistent lack of effective treatments, requiring novel approaches targeting mitochondrial metabolism and DNA repair pathways

MIRACLE Trial Design and Promising Early Efficacy Signals

Recent studies on acute myeloid leukemia have employed diverse trial designs ranging from retrospective cohort analyses to prospective multicenter trials. These studies have evaluated various patient populations, from newly diagnosed AML patients to those undergoing specific treatments like hematopoietic stem cell transplantation, with sample sizes varying from small exploratory cohorts to large multi-institutional databases.

Annamycin's Differentiated Safety Profile in R/R AML

Preclinical toxicology studies demonstrate that annamycin exhibits a distinct safety profile compared to conventional anthracyclines, with liposomal formulation significantly improving its therapeutic window. In acute toxicity studies in mice, free annamycin showed approximately twice the toxicity of doxorubicin (LD50 8.8 mg/kg versus 19.9 mg/kg), but liposomal encapsulation reduced annamycin toxicity by 2-fold to an LD50 of 15.74 mg/kg. The primary dose-limiting toxicity was granulocytopenia, which occurred more profoundly than with equitoxic doses of doxorubicin, indicating enhanced myelosuppressive activity.

The most clinically significant differentiation lies in annamycin's reduced cardiotoxicity profile. Chronic toxicity studies revealed that liposomal annamycin (L-Ann) demonstrated remarkably less cardiotoxic potential than doxorubicin, with cumulative toxicity assessments showing markedly lower body weight loss and mortality with weekly L-Ann administration compared to doxorubicin at equivalent fractions of subacute LD10 doses. Additionally, L-Ann exhibited reduced vesicant toxicity following intradermal administration, suggesting improved tolerability for extravasation events.

Cross-species validation in beagle dogs confirmed the favorable safety margin, with animals tolerating mouse-equivalent LD10 doses (1.4 mg/kg) without adverse effects, hematological parameter changes, or pathological findings. Formulation optimization studies further demonstrated that reducing liposome size from 1.6 to 0.03 microns decreased subacute toxicity by 2-fold, while phospholipid composition modifications had moderate effects on toxicity profiles. These data established L-Ann as more selectively myelotoxic than doxorubicin while maintaining a noncardiotoxic profile, supporting its advancement to Phase I clinical investigation.

Annamycin's Early Success Signals a Shift in R/R AML Therapy

The recent announcement regarding Annamycin's pivotal Phase 2B/3 MIRACLE trial offers a compelling glimpse into a potential paradigm shift for patients battling relapsed or refractory acute myeloid leukemia (R/R AML). The preliminary blinded data, showcasing composite complete remission rates exceeding 40% and complete remission rates around 30%, significantly outstrip the historical 17-18% observed with cytarabine alone. This is not merely an incremental improvement; it represents a substantial leap forward for a patient population desperately in need of more effective options, particularly those who have progressed after venetoclax-based regimens.

What makes Annamycin particularly noteworthy is its differentiated profile. Unlike conventional anthracyclines such as Adriamycin, Annamycin has demonstrated a significantly reduced cardiotoxicity, a critical safety advantage for AML patients who are often elderly or have pre-existing cardiac conditions. Furthermore, research indicates its enhanced efficacy against multidrug-resistant (MDR) cells, directly addressing a primary mechanism of treatment failure in R/R AML. This dual benefit of improved efficacy and a favorable safety profile positions Annamycin as a potentially transformative agent.

However, the path forward, while promising, is not without its considerations. The initial blinded data, while encouraging, awaits full confirmation upon the complete unblinding of the trial. The competitive landscape in R/R AML is dynamic, with continuous innovation, necessitating Annamycin to consistently deliver robust and durable clinical outcomes. Finally, navigating the complex regulatory environment will require a comprehensive data package that unequivocally demonstrates a favorable benefit-risk profile. Should these hurdles be successfully cleared, Annamycin could redefine treatment expectations for R/R AML, offering renewed hope to patients and clinicians alike.